Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria~* Active PsA defined as the presence of at least 3 (out of 68) tender and at least 3 (out of 66) swollen joints~* Presence of active plaque psoriasis with a BSA ≥3%~* Men must agree to use a reliable method of birth control or remain abstinent during the study~* Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~* Have had an inadequate response when treated with 1 or more conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)~Exclusion Criteria:~* Current or prior use of biologic agents for treatment of Ps or PsA~* Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA~* Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab~* Serious disorder or illness other than psoriatic arthritis~* Serious infection within the last 3 months~* Active Crohn's disease or active ulcerative colitis~* Active vasculitis or uveitis~* Diagnosis of or history of malignant disease \<5 years prior to randomization~* Women who are breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab (Type: EXPERIMENTAL): 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline for all participants.~80 mg ixekizumab given once every 2 weeks (Q2W) SC from week 2 to week 12 and once every 4 weeks (Q4W) thereafter for participants with moderate-to-severe plaque Ps.~80 mg ixekizumab given SC Q4W starting week 4 for participants not meeting criteria for moderate-to-severe plaque Ps.
- Adalimumab (Type: ACTIVE_COMPARATOR): 80 mg adalimumab given SC at baseline followed by 40 mg Q2W given SC starting week 1 for participants with moderate-to-severe plaque Ps.~40 mg adalimumab given Q2W SC at baseline followed by 40 mg Q2W starting at Week 2 given SC for participants not meeting criteria for moderate-to-severe plaque Ps.

Based on this trial design, predict the completion outcome and termination type (if applicable).